Table 2 The application of CSAN in the field of antitumor
Tumor type | Nano preparation | Drug composition | Effects | Characteristic | Refs. |
|---|---|---|---|---|---|
Lung cancer | UA NPs | UA | ↓Tumor proliferation and growth ↑Cell apoptosis,↑activation of CD4 + T cells | The ability of liver protection in vivo The potential for immunotherapy | [12] |
Lung cancer | PTX-BBR NPs | BBR | ↑ROS levels, ↑Block the cell cycle and cell apoptosis ↓Tumor growth | Mitochondria-targeting delivery Synergistic enhancement | [13] |
PTX | |||||
Lung cancer | Rb1/PPD NPs | Rb1 | ↑Accumulation at the tumor site, ↑Cytotoxicity ↑Blood circulation time, ↓Damage to normal tissues | Synergistic enhancement Simple, scalable, green economy process | [153] |
PPD | |||||
Breast Cancer | OA-GA-PTX NPs | OA | ↑Drug releasing capacity and Cellular uptake ↑Tumor aggregation targeting and apoptosis ↓Tumor proliferation and growth, ↑Block the cell cycle ↓ALT、AST、LDH、CK、MDA, ↑SOD、GSH | Synergistic enhancement Reduce chemotherapy side-effects Different antitumor mechanisms Reduce damage caused by oxidative stress | [29] |
GA | |||||
PTX | |||||
Breast Cancer | UA-PTX NPs | UA | ↓Tumor growth ↑Block the cell cycle, ↑Cell apoptosis and cellular uptake ↑Tumor aggregation targeting, ↑SOD、GSH | Synergistic enhancement Different antitumor mechanisms Reduce chemotherapy side-effects | [19] |
PTX | |||||
Breast Cancer | DTX/GBA-PLGA NPs | GA | ↑The expression of P-gp, ↑Cell apoptosis ↓Tumor growth | Synergistic enhancement Special in multidrug-resistant breast cancer | [81] |
DTX | |||||
Liver cancer | UEA NPs | UA | ↑Drug releasing capacity and cellular uptake, ↓Tumor growth, ↑IL-12、IFN-γ、CD4+、CD8+ ↑Tumor aggregation targeting, ↑Cytotoxicity | Synergistic enhancement Improvement of Th1/Th2 imbalance | [102] |
EGCG | |||||
DOX | |||||
Liver cancer | GL-HCPT micelles | GL | ↑Cytotoxicity, ↑Tumor aggregation targeting ↓Tumor growth | Improve the solubility and stability of HCPT Reducing the side effects of HCPT | [121] |
HCPT | |||||
Gastric cancer | SiCN | Cur | ↑Drug releasing capacity and cellular uptake ↑Cytotoxicity, ↑Endocytosis | Synergistic enhancement Self-monitoring function | [16] |
Irinotecan hydrochloride | |||||
Colorectal cancer | DOX-FA-GDNVs | GDNV | ↓Tumor proliferation and growth, ↑Cell apoptosis ↑Drug releasing capacity and targeting ability | Loading Dox with high efficiency | [92] |
DOX | |||||
Colorectal cancer | INP-DOX | INP | ↑Cytotoxicity, ↓Tumor growth | Synergistic enhancement PH-responsive | [74] |
DOX | |||||
Ovarian cancer | PTX-ss-TMP NPs | TMP | ↑Cytotoxicity and cell apoptosis, ↑Block the cell cycle ↑Drug releasing capacity and cellular uptake ↑Tumor aggregation targeting, ↓p-VEGFR2/VEGFR2, p-AKT/AKT, p-mTOR/mTOR and p-p38/p38 | Synergistic enhancement Redox-responsive drug release Anti-angiogenesis effect | [118] |
PTX | |||||
Cervical cancer | PTX-Cur coloaded PEG-PNB-TC | Cur | ↑Endocytosis and cellular uptake, ↑Cytotoxicity | Circumvented the PTX resistance in the MDR cancer cells | [167] |
PTX | |||||
Glioma | Pep-1/Bor/CMS-M | Bor | ↑Cytotoxicity and cell apoptosis, ↑Endocytosis and cellular uptake, ↓Tumor growth | Blood–brain barrier penetrating | [137] |
CMS | |||||
Neuroglioma | Lut-Fe3+ NPs | Lut | ↓Tumor proliferation, ↑Cytotoxicity | High oxidation stability Chemotherapy combined with PPT | [15] |
Melanoma | OPDMA-Cela NPs | Cela | ↑Pharmacokinetics, ↑Mitochondria targeting capacity ↓Tumor growth | Mitochondria-targeted carrier for drug delivery | [41] |